$TRDA
Entrada Therapeutics, Inc. Stock $trda

$trda Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000168937522000045 Filed on November 07, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.894M	$6.978M
YoY Change	62.25%	81.2%
% of Gross Profit
Research & Development	$15.69M	$18.96M
YoY Change	26.88%	80.33%
% of Gross Profit
Depreciation & Amortization	$525.0K	$500.0K
YoY Change	44.23%	66.67%
% of Gross Profit
Operating Expenses	$25.58M	$25.94M
YoY Change	38.56%	80.56%
Operating Profit		-$25.94M
YoY Change		80.56%
Interest Expense	$950.0K	$799.0K
YoY Change	7207.69%	-1310.61%
% of Operating Profit
Other Income/Expense, Net		$799.0K
YoY Change		-1310.61%
Pretax Income	-$24.63M	-$25.14M
YoY Change	33.51%	74.2%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$24.63M	-$25.14M
YoY Change	33.51%	74.2%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.80
Diluted Earnings Per Share	-$0.79	-$0.80
COMMON SHARES
Basic Shares Outstanding	31.41M shares	31.37M shares
Diluted Shares Outstanding		31.30M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$188.7M	$215.6M
YoY Change	-35.16%	76.45%
Cash & Equivalents	$45.16M	$53.31M
Short-Term Investments	$143.6M	$162.3M
Other Short-Term Assets	$21.16M	$19.16M
YoY Change	177.15%	1316.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$209.9M	$234.7M
YoY Change	-29.74%	90.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.681M	$7.444M
YoY Change	22.68%	26.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.210M	$954.0K
YoY Change	497.48%	-67.87%
Total Long-Term Assets	$42.18M	$39.73M
YoY Change	491.35%	347.91%
TOTAL ASSETS
Total Short-Term Assets	$209.9M	$234.7M
Total Long-Term Assets	$42.18M	$39.73M
Total Assets	$252.1M	$274.5M
YoY Change	-17.58%	107.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.990M	$1.341M
YoY Change	748.44%	-41.13%
Accrued Expenses	$7.576M	$11.95M
YoY Change	25.99%	144.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.97M	$21.55M
YoY Change	227.01%	201.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$17.53M	$19.69M
YoY Change	4326.77%	5760.54%
Total Long-Term Liabilities	$17.53M	$19.69M
YoY Change	4326.77%	5760.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.97M	$21.55M
Total Long-Term Liabilities	$17.53M	$19.69M
Total Liabilities	$39.50M	$41.24M
YoY Change	455.19%	450.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$188.3M	-$163.7M
YoY Change	101.03%	117.69%
Common Stock	$3.000K	$3.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$212.6M	$233.2M
YoY Change
Total Liabilities & Shareholders Equity	$252.1M	$274.5M
YoY Change	-17.58%	107.31%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$24.63M	-$25.14M
YoY Change	33.51%	74.2%
Depreciation, Depletion And Amortization	$525.0K	$500.0K
YoY Change	44.23%	66.67%
Cash From Operating Activities	-$27.30M	-$27.48M
YoY Change	32.92%	95.25%
INVESTING ACTIVITIES
Capital Expenditures	$708.0K	-$810.0K
YoY Change	-153.56%	0.5%
Acquisitions
YoY Change
Other Investing Activities	$19.50M	-$9.324M
YoY Change
Cash From Investing Activities	$18.79M	-$10.13M
YoY Change	-1521.48%	1157.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	358.0K	60.00K
YoY Change	-99.81%	-43.4%
NET CHANGE
Cash From Operating Activities	-27.30M	-27.48M
Cash From Investing Activities	18.79M	-10.13M
Cash From Financing Activities	358.0K	60.00K
Net Change In Cash	-8.154M	-37.56M
YoY Change	-104.83%	154.19%
FREE CASH FLOW
Cash From Operating Activities	-$27.30M	-$27.48M
Capital Expenditures	$708.0K	-$810.0K
Free Cash Flow	-$28.01M	-$26.67M
YoY Change	45.75%	101.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001689375
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40969
	dei	Entity Registrant Name EntityRegistrantName	ENTRADA THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3983399
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6 Tide Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19161000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7636000	usd
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02210
	dei	City Area Code CityAreaCode	857
	dei	Local Phone Number LocalPhoneNumber	520-9158
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	TRDA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31406165	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53311000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291064000	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	162261000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	234733000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	298700000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7444000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6261000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3950000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27382000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	954000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	872000	usd
CY2022Q3	us-gaap	Assets Assets	274463000	usd
CY2021Q4	us-gaap	Assets Assets	305833000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1341000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	706000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11951000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6013000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8259000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	21551000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6719000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19692000	usd
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	396000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	41243000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7115000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31393110	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31325373	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31336092	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31224336	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	399620000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	392384000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2747000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163656000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93669000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	233220000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298718000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	274463000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	305833000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18958000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10513000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50924000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23564000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6978000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3851000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20745000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9103000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	25936000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	14364000	usd
	us-gaap	Operating Expenses OperatingExpenses	71669000	usd
	us-gaap	Operating Expenses OperatingExpenses	32667000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-25936000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14364000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-71669000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32667000	usd
CY2022Q3	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	799000	usd
CY2021Q3	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-66000	usd
	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	1682000	usd
	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-44000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	799000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-66000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1682000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-44000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25137000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14430000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-69987000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32711000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.78
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-24.18
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-49669000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	212000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-24.18
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31298052	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31298052	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1475170	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1475170	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31273612	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31273612	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1352721	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1352721	shares
CY2022Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-482000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2747000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-482000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2747000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25619000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14430000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72734000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32711000	usd
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	85299885	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	81658000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-41490000	usd
CY2021Q1	trda	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	53522099	shares
CY2021Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	115831000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29000	usd
CY2021Q1	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	8000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	164000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8380000	usd
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	138821984	shares
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	197489000	usd
CY2021Q2	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	18000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	326000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-9901000	usd
CY2021Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	138821984	shares
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	197489000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-59014000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	106000	usd
CY2021Q3	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	170000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	577000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14430000	usd
CY2021Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	138821984	shares
CY2021Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	197489000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-72591000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298718000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000	usd
CY2022Q1	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	35000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1794000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1535000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21671000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	277391000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	usd
CY2022Q2	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	34000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2512000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-730000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-23179000	usd
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	256039000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	60000	usd
CY2022Q3	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	33000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2707000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-482000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25137000	usd
CY2022Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	233220000	usd
	us-gaap	Profit Loss ProfitLoss	-69987000	usd
	us-gaap	Profit Loss ProfitLoss	-32711000	usd
	us-gaap	Depreciation Depreciation	1370000	usd
	us-gaap	Depreciation Depreciation	753000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7013000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1068000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-255000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	82000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1923000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	694000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-153000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12020000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	449000	usd
	trda	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-5609000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	311000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6104000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2138000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5437000	usd
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	339000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66482000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30321000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2179000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3258000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	221977000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	56714000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-167442000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3258000	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	115831000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	121000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	347000	usd
	trda	Proceeds From Early Exercise Of Stock Options ProceedsFromEarlyExerciseOfStockOptions	0	usd
	trda	Proceeds From Early Exercise Of Stock Options ProceedsFromEarlyExerciseOfStockOptions	528000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	121000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116706000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-233803000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	83127000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	291064000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39045000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57261000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122172000	usd
	trda	Deferred Financing Costs In Accounts Payable And Accrued Expenses DeferredFinancingCostsInAccountsPayableAndAccruedExpenses	0	usd
	trda	Deferred Financing Costs In Accounts Payable And Accrued Expenses DeferredFinancingCostsInAccountsPayableAndAccruedExpenses	505000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	32000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	832000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	32991000	usd
	trda	Transfer Of Deposits For Equipment From Operating To Investing Cash Flows TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows	495000	usd
	trda	Transfer Of Deposits For Equipment From Operating To Investing Cash Flows TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows	0	usd
	trda	Vesting Of Options Early Exercised Subject To Repurchase VestingOfOptionsEarlyExercisedSubjectToRepurchase	102000	usd
	trda	Vesting Of Options Early Exercised Subject To Repurchase VestingOfOptionsEarlyExercisedSubjectToRepurchase	195000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-70000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32700000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163700000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	215600000	usd
CY2022Q3	trda	Number Of Securities NumberOfSecurities	36	security
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	162300000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53311000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291064000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	3950000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57261000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	291064000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	137967000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	136081000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossNoncurrent	27041000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	26180000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	165008000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	162261000	usd
CY2021Q4	us-gaap	Cash Cash	300000	usd
CY2022Q3	us-gaap	Cash Cash	300000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10220000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	485000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11951000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7677000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2776000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1416000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7444000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6261000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	500000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	300000	usd
	us-gaap	Depreciation Depreciation	1400000	usd
	us-gaap	Depreciation Depreciation	800000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6013000	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4033000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4077000	usd
CY2022Q3	trda	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	2620000	usd
CY2021Q4	trda	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	1032000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	563000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	419000	usd
CY2022Q3	trda	Accrued Tenant Improvements Current AccruedTenantImprovementsCurrent	4494000	usd
CY2021Q4	trda	Accrued Tenant Improvements Current AccruedTenantImprovementsCurrent	0	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	241000	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.83
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8088135	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6583887	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2707000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	578000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7013000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1068000	usd
CY2022Q3	trda	Unvested Shares From Early Exercises UnvestedSharesFromEarlyExercises	67737	shares
CY2021Q4	trda	Unvested Shares From Early Exercises UnvestedSharesFromEarlyExercises	111756	shares
CY2022Q3	trda	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount	200000	usd
CY2021Q4	trda	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount	300000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3461870	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.38
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1660987	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.34
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	57018	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.12
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	63109	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5002730	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.77
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2506844	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.16
CY2022Q3	us-gaap	Security Deposit SecurityDeposit	800000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9219000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9494000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8650000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2294000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	6479000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	2294000	usd
	us-gaap	Lease Cost LeaseCost	6479000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	6306000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M12D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0381
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2268000	usd
CY2022Q3	trda	Lessee Operating Lease Liability To Be Paid Due After Year Three LesseeOperatingLeaseLiabilityToBePaidDueAfterYearThree	0	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	29631000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1680000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	27951000	usd
CY2022Q1	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1 LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1	P10Y
CY2022Q1	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Renewal Term1 LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1	P5Y
CY2022Q1	trda	Operating Leases Rental Expenses Initial Fixed Monthly Rental Payments First12 Months OperatingLeasesRentalExpensesInitialFixedMonthlyRentalPaymentsFirst12Months	500000	usd
CY2022Q1	trda	Number Of Square Feet In Lease Agreement NumberOfSquareFeetInLeaseAgreement	65000	sqft
CY2022Q1	trda	Operating Leases Rental Expenses Annual Increase OperatingLeasesRentalExpensesAnnualIncrease	0.03
CY2022Q1	trda	Tenant Improvements Allowance TenantImprovementsAllowance	19500000	usd
CY2022Q1	trda	Initial Fixed Rental Income Per Rentable Square Foot Of Premises Per Annum InitialFixedRentalIncomePerRentableSquareFootOfPremisesPerAnnum	240.00
CY2022Q1	trda	Operating Leases Additional Allowance OperatingLeasesAdditionalAllowance	1600000	usd
CY2022Q1	trda	Tenant Allowance Rentable Square Foot Of Premises Per Annum TenantAllowanceRentableSquareFootOfPremisesPerAnnum	20.00
CY2022Q1	trda	Interest Rate For Additional Improvements Allowance InterestRateForAdditionalImprovementsAllowance	0.08
CY2022Q3	trda	Operating Lease Related Expenses Prior To Commencement OperatingLeaseRelatedExpensesPriorToCommencement	13700000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.78
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25137000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14430000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-69987000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32711000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31298052	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31298052	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1475170	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1475170	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31273612	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31273612	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1352721	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1352721	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-24.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-24.18
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5515912	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21691266	shares

Files In Submission

Name	View Source	Status
0001689375-22-000045-index-headers.html	Edgar Link	pending
0001689375-22-000045-index.html	Edgar Link	pending
0001689375-22-000045.txt	Edgar Link	pending
0001689375-22-000045-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trda-20220930.htm	Edgar Link	pending
trda-20220930.xsd	Edgar Link	pending
trda-20220930x10qex311.htm	Edgar Link	pending
trda-20220930x10qex312.htm	Edgar Link	pending
trda-20220930x10qex321.htm	Edgar Link	pending
trda-20220930_def.xml	Edgar Link	unprocessable
trda-20220930_cal.xml	Edgar Link	unprocessable
trda-20220930_pre.xml	Edgar Link	unprocessable
trda-20220930_lab.xml	Edgar Link	unprocessable
trda-20220930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRDA
Entrada Therapeutics, Inc. Stock $trda

2022 Q4 Form 10-Q Financial Statement

#000168937522000045 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRDA Entrada Therapeutics, Inc. Stock $trda

2022 Q4 Form 10-Q Financial Statement

#000168937522000045 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRDA
Entrada Therapeutics, Inc. Stock $trda